2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses copanlisib (Aliqopa) in follicular lymphoma.
Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses copanlisib (Aliqopa) in follicular lymphoma.
The intravenous pan-class I PI3K inhibitor copanlisib has shown predominant activity against the PI3K-alpha and -delta isoforms in follicular lymphoma.
Winter says that the category of PI3K inhibitors continues to grow in this disease, and this class of agents will positively add to the armamentarium.
Related Content: